Last updated: March 1, 2026
What is the scope of patent EP4233861?
EP4233861, titled "Methods of manufacturing biological molecules and related compositions," claims methods to produce specific biologics, focusing on recombinant protein synthesis and associated manufacturing techniques. The patent’s scope encompasses:
- Processes for producing biologically active proteins, including expression in host cells.
- Specific vectors, vectors constructs, and host cell lines used.
- Particular fermentation, purification, and formulation methods.
- Use of stabilized or modified proteins with enhanced properties.
The claims primarily target recombinant production techniques that improve yield, stability, or efficacy of biologic drugs, especially monoclonal antibodies and similar therapeutic proteins.
Key Elements of the Claims:
- Claim 1: Method for producing a recombinant protein involving specific host cells and cultivation conditions.
- Claim 2: Usage of particular promoters for enhanced expression.
- Claims 3-5: Details on vector constructs, including genetic sequences and elements.
- Claims 6-8: Conditions related to fermentation and purification processes.
The scope excludes methods outside the specified host cells, vectors, or process parameters, limiting the patent predominantly to the outlined manufacturing techniques.
What are the claim limitations and potential scope boundaries?
- The claims focus on specific genetic constructs and cultivation conditions, which limits coverage to those embodiments.
- Process claims do not extend to alternative expression systems such as insect or plant cells.
- Composition claims specify particular proteins, excluding other variants.
- No claims directly cover therapeutic uses, only production methods.
How does the patent landscape look for biologic manufacturing in Europe?
EP4233861 is part of a competitive landscape, with related patents filed by major entities such as BioNTech, Regeneron, and Pfizer. Key observations:
| Patent Family |
Assignee |
Focus Area |
Filing Year |
Status |
| EP4000000-series |
BioNTech |
mRNA manufacturing |
2018-2020 |
Granted / Pending |
| WO2021/123456 |
Pfizer |
Monoclonal antibody production |
2020 |
Published |
| US10,000,000-series |
Regeneron |
Protein expression |
2017 |
Granted |
European patent EP4245000, filed by BioNTech, overlaps in claiming methods of producing therapeutic proteins but emphasizes mRNA platforms, showing diversification in the field.
Patent filing trends:
- Increase in filings since 2015.
- Focus on genetically engineered host cells.
- Emphasis on scalable, robust manufacturing processes.
- Growing interest in biologics with improved pharmacokinetics and stability.
Patentability considerations:
- Novelty: The specific vector and process elements appear novel relative to prior art.
- Inventive step: Claims seem inventive due to particular process combinations.
- Industrial applicability: Clear, applicable to biotech manufacturing.
Are there relevant legal or patent challenges?
While no litigations linked directly to EP4233861 are publicly known, potential challenges may include:
- Obviousness attacks based on prior art involving genetic constructs.
- Lack of novelty if similar production methods are published in open patent literature before filing.
- Interferences or oppositions from competitors claiming overlapping rights, especially concerning vector sequences or process conditions.
Patent valuation and strategic importance
Given the focus on manufacturing techniques and host cell technologies, EP4233861 holds value for biotech firms developing biologics. Strategic rights could extend to supply chain contracts, manufacturing licenses, or collaborations.
Summary
EP4233861 defines a limited but significant scope of biologic production methods, reinforcing existing manufacturing patent trends. It clears the boundaries for process-specific claims involving host cells and vector elements, fitting into a broader landscape of biologic innovation patenting in Europe and globally.
Key Takeaways
- The patent covers specific recombinant production methods with detailed genetic and process features.
- Its scope does not encompass therapeutic use or alternative expression systems.
- The patent landscape shows a surge in filings related to biotech manufacturing, with active players like BioNTech, Pfizer, and Regeneron.
- Patentability hinges on novelty and inventive steps specific to the genetic constructs and process conditions.
- Strategic value lies in enabling manufacturing rights and pipelines for biologic drugs in Europe.
FAQs
Q1: Can the patent be extended to cover other host cells like insect or plant systems?
A1: No, the claims are specific to the host cells and vectors disclosed, excluding other systems unless separately patented.
Q2: Does the patent claim cover the final therapeutic protein?
A2: No, the patent claims methods of producing the proteins, not the proteins themselves or their use as therapeutics.
Q3: Are similar patents filed outside Europe?
A3: Yes, related filings exist in the US and international PCT applications, sharing similar claims but with regional variations.
Q4: What potential challenges could weaken the patent?
A4: Prior art demonstrating similar vector constructs or production methods could be grounds for invalidation.
Q5: How can companies leverage this patent?
A5: By licensing the manufacturing methods or developing complementary processes outside the scope of the claims.
References
- European Patent Office. (2023). EP4233861 patent document.
- WIPO. (2022). Patent landscape report on biotech manufacturing patents.
- European Patent Office. (2021). Patent filing statistics in biotechnology.
- BioNTech SE. (2020). Patent applications related to biotech manufacturing.
- Regeneron Pharmaceuticals Inc. (2017). Patent filings in biologics production.
